Novartis And Aurobindo Scrap $900M Deal Amid FTC Probe
Swiss pharmaceutical giant Novartis AG has called off a planned $900 million deal to sell a portion of its U.S. Sandoz portfolio to Aurobindo Pharma USA after the companies were unable...To view the full article, register now.
Already a subscriber? Click here to view full article